Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
Part of paid clinical trials in Buffalo, New York.
- Sponsor
- JSR Medical Co., Ltd.
- Study ID
- NCT05826743
- Status
- Recruiting
Conditions
- Anastomotic Leakage
- Colorectal Cancer
- Colorectal Surgery
- Ileostomy - Stoma
- Rectal/Anal
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - 80 Years
- Healthy Volunteers
- Accepted
Interventions
- COLO BT™ — DEVICEA removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma after surgery for only patients who need it (do not have a healed anastomosis)
- Stoma Creation — OTHERProtective ileostomy
Study Details
The purpose of this study is to evaluate the Colorectal Balloon Tube (hereinafter referred to as COLO-BT™) device, a single use, temporary intraluminal bypass device, intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic)
Key Dates
- Start date
- Dec 4, 2023
- Status verified
- Jun 2025
- Primary completion
- Dec 15, 2026
- Completion
- Mar 15, 2027
Study Design
- Enrollment
- 256 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: COLO BT™Patients receive COLO BT™ during colorectal surgery.
- Active Comparator: Standard of CarePatients receive the standard of care, a protective stoma, during colorectal surgery.
Primary Outcome Measure
Study Success Case(Avoidance of ostomy) [ Time Frame: 24 Weeks ]
Central Contacts
- Kim+82-10-9345-1058
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo | Buffalo | New York | 14203 | |
| PennState Health - Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | |
| Baylor College of Medicine | Houston | Texas | 77030 |
Find similar trials in Buffalo, NY
By condition
By specialty
Related Studies
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesPHASE1/PHASE2 · Recruiting · Anwaar Saeed · Westwood, Kansas
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPHASE1/PHASE2 · Recruiting · IDEAYA Biosciences · Los Angeles, California